SAN DIEGO, June 10, 2008 (PRIME NEWSWIRE) -- Asphelia Pharmaceuticals, a privately-held, clinical-stage company focused on the development of novel therapeutics for the treatment of immunological disorders, will be presenting at the 2008 BIO International Convention on June 19th at 3PM PT in Room 5A of the San Diego Convention Center. The Biotechnology Industry Organization (BIO) is a trade association that hosts the BIO International Convention, to be held this year in San Diego, CA from June 17th to June 20th. BIO is the world's largest biotechnology organization, providing advocacy, business development, and communications services to more than 1,150 members worldwide.
Francois-Xavier Frapaise MD, President and CEO of Asphelia, will provide an overview of Asphelia's core-assets, including a trichuris suis ova-based therapy (ASP 1002) and an oral integrin and adhesion molecule antagonist (ASP 2002). Dr. Frapaise's presentation will be focused on the immunomodulating effects of Helminths and the use of this novel therapeutic approach in the treatment of immunological disorders such as Crohn's Disease, Multiple Sclerosis, as well as allergic conditions. The Helminths technology is currently being assessed in a number of clinical studies being conducted globally. Dr. Frapaise will also be available for individual meetings before and after his presentation.
About Asphelia Pharmaceuticals, Inc.
Asphelia Pharmaceuticals is a privately-held, clinical-stage company poised to change the course of immunological disorders. Asphelia is focused on the development of therapies for Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), as well as other immunological and inflammatory disorders, including Multiple Sclerosis and Asthma. Asphelia's core assets target the causes of Inflammatory Bowel Disease, not just its symptoms, providing viable alternatives to the current standards of care.